You are here

Prices & Quotes - UK Markets - Novacyt S.A. (CDI) (NCYT)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Share Price:
Down 180.70p
Change Today:
-3.10p
Market Cap:
127.62m
Sector:
Medical Equipment and Services

Novacyt flags possible 3m hit from Covid test regulations change

By Josh White

Date: Tuesday 02 Nov 2021

LONDON (ShareCast) - (Sharecast News) - Clinical diagnostics specialist Novacyt updated the market on the availability of its Covid-19 tests in the UK on Tuesday, following the implementation of amendments to the UK Health Security Agency's coronavirus test device regulations, or 'CTDA'.
The AIM-traded firm said the mandatory CTDA guidelines would require all suppliers of Covid-19 tests, including both polymerase chain reaction (PCR) and lateral flow tests, to submit data on the tests for a desktop validation if they wished to continue to sell them in the UK.

It said the legislation would not apply or affect any sales outside the UK.

On 20 October, the UK Health Security Agency issued a list of products on the CTDA register that had so far successfully completed such a desktop review and been approved.

A second list, the 'temporary protocol', was also issued, detailing products which could remain on the market while validation was being processed, with an extended deadline from 1 November to 28 February.

Only validated products, or products on the temporary protocol could be sold in the UK after 31 October.

The company said the UK Health Security Agency had committed to continuing its review of submitted tests, and updating the CTDA register accordingly.

"Novacyt submitted 11 products for review on time to meet the original CTDA submission deadline of 1 September," the board said in its statement.

"To date, Novacyt's 'Primerdesign PROmate' Covid-19 test has been named on the temporary protocol," it added, confirming that it encompassed both the PROmate 1 Gene q16 and q32 products.

It said the CTDA had not yet communicated the status of any of the remaining nine products.

"As a result, from 1 November, the company will only be selling the PROmate Covid-19 test in the UK until the UK Health Security Agency completes its review of the additional nine products submitted.

"If no further products are added to the CTDA register, the impact on full year revenues for 2021 will be around 3m."

At 1227 GMT, shares in Novacyt were down 2.46% at 248p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

NCYT Market Data

Currency UK Pounds
Price 180.70p
Change Today -3.10p
52 Week High 1,158.00p
52 Week Low 171.33p
Volume 1,265,722
Shares Issued 70.63m
Market Cap 127.62m
Beta 0.10

Performance Indicators

Compare performance with the sector and the market.

Key
Vs Market
Vs Sector
Value
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. half market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
Price Trend
market
  1. full market star
  2. half market star
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. half sector star
  3. empty sector
  4. empty sector
  5. empty sector
Income
Not Available
Growth
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. half sector star
Price Chg 6m
market
  1. half market star
  2. empty market
  3. empty market
  4. empty market
  5. empty market
sector
  1. full sector star
  2. empty sector
  3. empty sector
  4. empty sector
  5. empty sector
P/E
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. full market star
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star
PEG
market
  1. full market star
  2. full market star
  3. full market star
  4. half market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. half sector star
  4. empty sector
  5. empty sector
Dividend Yield
Not Available
EPS Growth
Not Available
Operating Margin
market
  1. full market star
  2. full market star
  3. full market star
  4. full market star
  5. empty market
sector
  1. full sector star
  2. full sector star
  3. full sector star
  4. full sector star
  5. full sector star

NCYT Dividends

No dividends found

Trades for 26-Jan-2022

Time Volume / Share Price
14:36 477 @ 180.70p
14:36 500 @ 180.70p
14:35 2,000 @ 180.96p
14:34 114 @ 180.20p
14:33 441 @ 180.20p

NCYT Key Personnel

CFO James McCarthy
CEO David Allmond